Managing bone and joint infection in children

Faust, Saul N; Clark, Julia; Pallett, A.; Clarke, Nicholas

doi:10.1136/archdischild-2011-301089

Cited by 87 publications

(100 citation statements)

References 65 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eleven samples were fluids including pus, two were blood cultures and one was tissue. Although a higher frequency than previously reported, 1 this study was conducted during the time of a reported outbreak of GAS infections nationwide in the UK. 70 Two patients (ages 5.2 years and 0.8 months) were found to have OM/SA due to S. pneumoniae.…”

mentioning

confidence: 67%

“…1 As no children aged ≤ 2 months were included in this microbiology substudy, this finding is not unexpected as GBS infections are rare in older infants and children.…”

mentioning

confidence: 90%

“…The diagnosis of OM or SA is made on the basis of clinical presentation, laboratory tests, imaging and, where available, microbiology results. 1 White blood cell count, C-reactive protein and erythrocyte sedimentation rate…”

Section: Clinical Featuresmentioning

confidence: 99%

“…1 This means that the true spectrum of organisms causing bone and joint infections in the UK is not known, and treatment is usually empirical.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Sukhtankar

Arch

Ahmad

et al. 2017

Health Technol Assess

Self Cite

View full text Add to dashboard Cite

Declared competing interests of authors: Saul N Faust was UK chief investigator and University Hospital Southampton NHS Foundation Trust principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All funds were paid into accounts within the NHS trust or university and not paid as personal fees. He reports consultancy fees for advisory board participation paid into accounts within the NHS trust or university (not personal fees) from vaccine manufacturers and antimicrobial agent manufacturers, including AstraZeneca, Cubist, Merck, GlaxoSmithKline (GSK) and Pfizer, outside the submitted work. He acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/ University of Southampton that are sponsored by vaccine manufacturers and antimicrobial agents, and has participated in advisory boards for vaccine manufacturers. Adam Finn reports grants and personal fees from Sanofi Pasteur MSD Ltd (SPMSD), and grants and personal fees from GSK, outside the submitted work. In addition, prior to October 2014, the University of Bristol and University Hospitals Bristol NHS Foundation Trust received funding for research conducted by Adam Finn and for consultancy and lectures from Pfizer, GSK, SPMSD and Novartis, who manufacture licensed and developmental meningococcal vaccines. Stuart C Clarke acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receive no personal payments from them. He has participated in advisory boards for vaccine manufacturers and has received financial assistance from vaccine manufacturers to attend conferences, but receives no personal payments for this work. All grants and honoraria are paid into accounts within the respective NHS trusts or universities. Jethro Herberg reports that he was an investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis; he received no personal payments. Andrew Riordan reports that the trust, but not he, has received funding for research sponsored by vaccine manufacturers and antimicrobial agents. He was lead editor for an e-learning package on meningitis produced by the Royal College of Paediatric and Child Health, funded by an unrestricted grant from Novartis Vaccines. Marieke Emonts was Newcastle upon Tyne Hospitals Foundation Trust's principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All grants and honoraria are paid into accounts within the NHS trust or university; she received no personal payment of any kind. Marieke Emonts reports acting as site principle investigator on behalf of the Newcastle upon Tyne Hospitals Foundation Trust/Newcastle University for clinical tr...

show abstract

mentioning

confidence: 67%

“…1 As no children aged ≤ 2 months were included in this microbiology substudy, this finding is not unexpected as GBS infections are rare in older infants and children.…”

mentioning

confidence: 90%

Section: Clinical Featuresmentioning

confidence: 99%

“…1 This means that the true spectrum of organisms causing bone and joint infections in the UK is not known, and treatment is usually empirical.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Sukhtankar

Arch

Ahmad

et al. 2017

Health Technol Assess

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the case of unifocal osteomyelitis continuation of treatment for six weeks and in the case of complex disease, defined as multifocal, significant bone destruction, resistant unusual pathogen, septic shock, continuation for more than six weeks to months might be required. Antimicrobial treatment is frequently administered intravenously for two to three weeks and then switched to oral medication [52]. Surgery is indicated to drain acute abscesses or when no improvement is achieved with antibiotic treatment.…”

Section: Treatmentmentioning

confidence: 99%